strontium ranelate (Protelos)
Jump to navigation
Jump to search
Introduction
Tradename: Protelos (not yet FDA approved 2004)
Indications
- osteoporosis
- strontium-89 used as radiopharmaceutical in the treatment of pain from bone metastases
Dosage
682 mg of elemental strontium/day
Adverse effects
- may result in defective bone growth
Mechanism of action
- Sr+2 can replace Ca+2 in bone tissue
- seems to decrease risk of osteoporosis in postmenopausal women
More general terms
Additional terms
References
- ↑ Prescriber's Letter 11(3):17 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200314&pb=PRL (subscription needed) http://www.prescribersletter.com